Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 11/2019

01-11-2019 | Fracture Healing | Original Article

Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study

Authors: H.-K. Min, J.-H. Ahn, K.-Y. Ha, Y.-H. Kim, S.-I. Kim, H.-Y. Park, K.-W. Rhyu, Y.-Y. Kim, I.-S. Oh, J.-Y. Seo, D.-G. Chang, J.-H. Cho

Published in: Osteoporosis International | Issue 11/2019

Login to get access

Abstract

Summary

Effects of anti-osteoporosis medications such as anti-resorptive and anabolic agents on healing of osteoporotic spinal fracture were retrospectively investigated. The use of anabolic agent significantly enhanced fracture healing, reduced progressive collapse, and presented good pain relief. These findings suggest that proper selection of medication could improve initial management of acute osteoporotic spinal fractures (OSFs).

Introduction

Although anti-osteoporosis medications have beneficial effects on prevention of osteoporotic spinal fractures (OSFs), few studies have compared effects of medications on fracture healing following OSFs. Therefore, the purpose of this study was to elucidate the effects of different anti-osteoporosis medications on radiological and clinical outcomes after acute OSFs.

Methods

A total of 132 patients diagnosed with acute OSFs were enrolled and allocated into three groups [group I (n = 39, no anti-osteoporosis medication), group II (n = 66, bisphosphonate), and group III (n = 27, parathyroid hormone (PTH)]. Radiological parameters including magnetic resonance (MR) classification, occurrence of intravertebral cleft (IVC), and clinical outcomes such as numerical rating scale (NRS) and Oswestry disability index were assessed. Risk analyses for IVC and progressive collapse were done along the related factors and medication type.

Results

IVC sign was observed in 30 patients. The rate of IVC sign was lower in group III (7.4%) than that in group I (20.5%) or group II (30.3%), although the difference was not statistically significant. Moreover, the degree of NRS improvement was better in group III than that in group I or group II (5.7 vs. 3.1 vs. 3.5, p < 0.001). On multiple regression analysis, mid-portion type fracture in MR classification was a significant risk factor for progressive OSFs. The use of PTH showed significant lower incidences of occurrence of IVC (odds ratio (OR) = 0.160) and increase in height loss (OR = 0.325).

Conclusions

Different anti-osteoporosis medications presented different clinical and radiological results after acute OSFs. The use of anabolic agent significantly enhanced fracture healing, reduced progressive collapse, and presented better clinical outcomes. Proper selection of medication might improve initial management of acute OSFs.
Literature
1.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465–475CrossRef
2.
Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G (2017) Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int 28:1531–1542CrossRef
3.
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRef
4.
Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30:934–944CrossRef
5.
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRef
6.
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 20:1–406CrossRef
7.
Endo Y, Kumamoto H, Nakamura M, Sugawara S, Takano-Yamamoto T, Sasaki K, Takahashi T (2017) Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Biol Pharm Bull 40:739–750CrossRef
8.
Schilcher J, Koeppen V, Aspenberg P, Michaelsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86:100–107CrossRef
9.
Colon-Emeric C, Nordsletten L, Olson S et al (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22:2329–2336CrossRef
10.
Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML (2009) Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 34:595–602CrossRef
11.
Matos MA, Tannuri U, Guarniero R (2010) The effect of zoledronate during bone healing. J Orthop Traumatol 11:7–12CrossRef
12.
Saito M, Shiraishi A, Ito M, Sakai S, Hayakawa N, Mihara M, Marumo K (2010) Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 46:1170–1179CrossRef
13.
Ha KY, Park KS, Kim SI, Kim YH (2016) Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing? Osteoporos Int 27:483–488CrossRef
14.
Potts JT (2005) Parathyroid hormone: past and present. J Endocrinol 187:311–325CrossRef
15.
Kraenzlin ME, Meier C (2011) Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7:647–656CrossRef
16.
Aspenberg P, Johansson T (2010) Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 81:234–236CrossRef
17.
Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93:1583–1587CrossRef
18.
Tsuchie H, Miyakoshi N, Kasukawa Y, Nishi T, Abe H, Segawa T, Shimada Y (2016) The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture. J Bone Miner Metab 34:86–91CrossRef
19.
Langdahl BL, Ljunggren O, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E (2016) Fracture rate, quality of life and Back pain in patients with osteoporosis treated with Teriparatide: 24-month results from the extended Forsteo observational study (ExFOS). Calcif Tissue Int 99:259–271CrossRef
20.
Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, Glass EV, Krege JH (2006) Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 17:1630–1637CrossRef
21.
Ha KY, Kim YH (2013) Risk factors affecting progressive collapse of acute osteoporotic spinal fractures. Osteoporos Int 24:1207–1213CrossRef
22.
Jahng JS, Kim HW (2000) Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics 23:1089–1094PubMed
23.
Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42:90–97CrossRef
24.
Seki S, Hirano N, Kawaguchi Y, Nakano M, Yasuda T, Suzuki K, Watanabe K, Makino H, Kanamori M, Kimura T (2017) Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J 26:2121–2127CrossRef
25.
Ha YC, Park YG, Nam KW, Kim SR (2015) Trend in hip fracture incidence and mortality in Korea: a prospective cohort study from 2002 to 2011. J Korean Med Sci 30:483–488CrossRef
26.
Aspenberg P, Malouf J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Caeiro JR, Marin F (2016) Effects of Teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: results of a randomized, active-controlled, double-blind clinical trial at 26 weeks. J Bone Joint Surg Am 98:1868–1878CrossRef
27.
Sudo H, Ito M, Abumi K, Kotani Y, Takahata M, Hojo Y, Minami A (2010) One-stage posterior instrumentation surgery for the treatment of osteoporotic vertebral collapse with neurological deficits. Eur Spine J 19:907–915CrossRef
28.
Yasuda H, Hoshino M, Tsujio T et al (2017) Difference of clinical course between cases with bone union and those with delayed union following osteoporotic vertebral fractures. Arch Osteoporos 13:3CrossRef
29.
Nakamae T, Fujimoto Y, Yamada K, Hiramatsu T, Hashimoto T, Olmarker K, Adachi N (2017) Relationship between clinical symptoms of osteoporotic vertebral fracture with intravertebral cleft and radiographic findings. J Orthop Sci 22:201–206CrossRef
30.
Ha KY, Kim YH, Chang DG, Son IN, Kim KW, Kim SE (2013) Causes of late revision surgery after bone cement augmentation in osteoporotic vertebral compression fractures. Asian Spine J 7:294–300CrossRef
31.
Kim YC, Kim YH, Ha KY (2014) Pathomechanism of intravertebral clefts in osteoporotic compression fractures of the spine. Spine J 14:659–666CrossRef
32.
Libicher M, Appelt A, Berger I, Baier M, Meeder PJ, Grafe I, Dafonseca K, Noldge G, Kasperk C (2007) The intravertebral vacuum phenomen as specific sign of osteonecrosis in vertebral compression fractures: results from a radiological and histological study. Eur Radiol 17:2248–2252CrossRef
33.
Fabbriciani G, Pirro M, Floridi P, Callarelli L, Manfredelli MR, Scarponi AM, Mannarino E (2012) Osteoanabolic therapy: a non-surgical option of treatment for Kummell’s disease? Rheumatol Int 32:1371–1374CrossRef
34.
Iwata A, Kanayama M, Oha F, Hashimoto T, Iwasaki N (2017) Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: a retrospective comparative study. BMC Musculoskelet Disord 18:148CrossRef
35.
Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150CrossRef
36.
Kitaguchi K, Kashii M, Ebina K, Sasaki S, Tsukamoto Y, Yoshikawa H, Murase T (2019) Effects of weekly teriparatide administration for vertebral stability and bony union in patients with acute osteoporotic vertebral fractures. Asian Spine J. https://​doi.​org/​10.​1007/​s00198-019-05111-6
37.
Dohke T, Iba K, Hanaka M, Kanaya K, Okazaki S, Yamashita T (2018) Teriparatide rapidly improves pain-like behavior in ovariectomized mice in association with the downregulation of inflammatory cytokine expression. J Bone Miner Metab 36:499–507CrossRef
38.
Park HY, Ahn JH, Ha KY, Kim YH, Kim SI, Min HK, Oh IS, Seo JY, Park SH (2018) Clinical and radiologic features of osteoporotic spine fracture with delayed neurologic compromises. World Neurosurg 120:e1295–e1300CrossRef
Metadata
Title
Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study
Authors
H.-K. Min
J.-H. Ahn
K.-Y. Ha
Y.-H. Kim
S.-I. Kim
H.-Y. Park
K.-W. Rhyu
Y.-Y. Kim
I.-S. Oh
J.-Y. Seo
D.-G. Chang
J.-H. Cho
Publication date
01-11-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 11/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-05125-0

Other articles of this Issue 11/2019

Osteoporosis International 11/2019 Go to the issue

Case Report

Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment

Letter to the Editor

FGF 23 and trabecular microarchitecture

Original Article

Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study

Original Article

Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents

Original Article

Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta

Original Article

Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy